Page 13«..10..12131415..2030..»

Virbac 2024 half-year results

Posted: September 15, 2024 at 2:45 am

1adjusted current operating income corresponds to the “current operating income before amortization of assets arising from acquisitions”2growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year), and excluding material change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year. This change is calculated on the actual scope of consolidation, including the impact of acquisitions (Globion and Sasaeah), for which the indicator in question is calculated on the basis of the previous year's exchange rate3net debt corresponds to current (€187.3 million) and non-current (€187.4 million) financial liabilities as well as a lease obligation related to the application of IFRS 16 (€37 million), less the cash position and cash equivalents (€156.8 million) as published in the statement of financial position4net cash position as of December 31, 20235operating cash flow corresponds to adjusted current operating income (€150.4 million) restated for items having no impact on the cash position as well as impact arising from asset disposal. This restates depreciation and amortization of fixed assets before acquisitions for €22.5 million (comprising €24.2 million in depreciation and amortization of fixed assets and provisions, and €-1.6 million in amortization of assets from acquisitions), as well as non-current income and expenses (€2 million), other non-cash income and expenses (€0.4 million), and impact of disposals (€1.3 million)

Original post:
Virbac 2024 half-year results

Posted in Global News Feed | Comments Off on Virbac 2024 half-year results

Virbac: Information on the departure of Sébastien Huron

Posted: September 15, 2024 at 2:45 am

At its meeting on September 13, 2024, the board of directors acknowledged the resignation of Sébastien Huron, effective as of September 27, 2024, from his positions as chief executive officer of Virbac and director of Virbac Limited (UK).

Continued here:
Virbac: Information on the departure of Sébastien Huron

Posted in Global News Feed | Comments Off on Virbac: Information on the departure of Sébastien Huron

Virbac : the board of directors announces a capital reduction through cancellation of treasury shares

Posted: September 15, 2024 at 2:45 am

Focusing on animal health, from the beginningAt Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals’ quality of life and to shaping together the future of animal health.

Read the rest here:
Virbac : the board of directors announces a capital reduction through cancellation of treasury shares

Posted in Global News Feed | Comments Off on Virbac : the board of directors announces a capital reduction through cancellation of treasury shares

Virbac : Public release of the Half-Year Financial Report at 30 June 2024.

Posted: September 15, 2024 at 2:45 am

Public release of the Half-Year Financial Report at 30 June 2024.

The rest is here:
Virbac : Public release of the Half-Year Financial Report at 30 June 2024.

Posted in Global News Feed | Comments Off on Virbac : Public release of the Half-Year Financial Report at 30 June 2024.

Virbac : Half-yearly financial report 2024

Posted: September 15, 2024 at 2:45 am

Please find attached 2024 Half-yearly financial report of Virbac

Read the original post:
Virbac : Half-yearly financial report 2024

Posted in Global News Feed | Comments Off on Virbac : Half-yearly financial report 2024

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Posted: September 15, 2024 at 2:45 am

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP

Read more:
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Posted in Global News Feed | Comments Off on Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Posted: September 15, 2024 at 2:45 am

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determination Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had not regained compliance with the Market Value of Listed Securities (“MVLS”) Requirement and the Market Value of Publicly Held Shares (“MVPHS”) requirement by September 9, 2024.

More here:
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Posted in Global News Feed | Comments Off on Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Posted: September 15, 2024 at 2:45 am

MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Edesa”), when combined with a series of transactions (the “Transactions”) that have occurred since the date of the most recent early warning report filed by Dr. Nijhawan on November 18, 2022 (the “Previous Report”), Dr. Nijhawan has acquired “beneficial ownership” of common shares in the capital of Edesa (“Common Shares”) in an amount equal to more than 2% of the issued and outstanding Common Shares since the date of the Previous Report.

Go here to read the rest:
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Posted in Global News Feed | Comments Off on Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Company Statement on FDA Advisory Committee Meeting  

Posted: September 15, 2024 at 2:45 am

MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) met today to discuss Intercept’s supplemental New Drug Application (sNDA) for OCALIVA® (obeticholic acid, OCA) for the treatment of primary biliary cholangitis (PBC) – a rare, progressive disease that disproportionally affects women. The sNDA was submitted to support full approval of OCALIVA and to satisfy post-marketing requirements confirming a clinical benefit in patients with PBC.

See the article here:
Company Statement on FDA Advisory Committee Meeting  

Posted in Global News Feed | Comments Off on Company Statement on FDA Advisory Committee Meeting  

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of…

Posted: September 15, 2024 at 2:45 am

- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting- iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET

See the original post:
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of...

Posted in Global News Feed | Comments Off on iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of…

Page 13«..10..12131415..2030..»